参考文献/References:
[1] SIEPER J,PODDUBNYY D. Axial spondyloarthritis[J]. Lancet,2017,390(10089):73-84.
[2] DE WINTER J J,VAN MENS L J,VAN DER HEIJDE D,et al. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis:a meta-analysis[J]. Arthritis Res Ther,2016,18:196-201.
[3] LANDEWé R,DOUGADOS M,MIELANTS H,et al. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine[J]. Ann Rheum Dis,2009,68(6):863-867.
[4] FRANKE L C,AMENT A J,VAN DE LAAR M A,et al. Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis[J]. Clin Exp Rheumatol,2009,27(4 Suppl 55):S118-S123.
[5] DE BARI C,DELL'ACCIO F,TYLZANOWSKI P,et al. Multipotent mesenchymal stem cells from adult human synovial membrane[J]. Arthritis Rheum,2001,44(8):1928-1942.
[6] DE BARI C,DELL'ACCIO F,VANLAUWE J,et al. Mesenchymal multipotency of adult human periosteal cells demonstrated by single-cell lineage analysis[J]. Arthritis Rheum,2006,54(4):1209-1221.
[7] DE BARI C,DELL'ACCIO F,LUYTEN F P. Human periosteum-derived cells maintain phenotypic stability and chondrogenic potential throughout expansion regardless of donor age[J]. Arthritis Rheum,2001,44(1):85-95.
[8] MARINOVA-MUTAFCHIEVA L,TAYLOR P,FUNA K,et al. Mesenchymal cells expressing bone morphogenetic protein receptors are present in the rheumatoid arthritis joint[J]. Arthritis Rheum,2000,43(9):2046-2055.
[9] BINKS D A,GRAVALLESE E M,BERGIN D,et al. Role of vascular channels as a novel mechanism for subchondral bone damage at cruciate ligament entheses in osteoarthritis and inflammatory arthritis[J]. Ann Rheum Dis,2015,74(1):196-203.
[10] KLAR R M. The induction of bone formation:the translation enigma[J]. Front Bioeng Biotechnol,2018,6:74-80.
[11] LORIES R J,MATTHYS P,DE VLAM K,et al. Ankylosing enthesitis,dactylitis,and onychoperiostitis in male DBA/1 mice:a model of psoriatic arthritis[J]. Ann Rheum Dis,2004,63(5):595-598.
[12] LEFEBVRE V,BHATTARAM P. Vertebrate skeletogenesis[J]. Curr Top Dev Biol,2010,90:291-317.
[13] LORIES R. The balance of tissue repair and remodeling in chronic arthritis[J]. Nat Rev Rheumatol,2011,7(12):700-707.
[14] LORIES R J,SCHETT G. Pathophysiology of new bone formation and ankylosis in spondyloarthritis[J]. Rheum Dis Clin N Am,2012,38(3):555-567.
[15] FRANCOIS R J,GARDNER D L,DEGRAVE E J,et al. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis[J]. Arthritis Rheum,2000,43(9):2011-2024.
[16] APPEL H,MAIER R,LODDENKEMPER C,et al. Immunohistochemical analysis of osteoblasts in zygapophyseal joints of patients with ankylosing spondylitis reveal repair mechanisms similar to osteoarthritis[J]. J Rheumatol,2010,37(4):823-828.
[17] XIONG J,CHEN J,TU J,et al. Association of HLA-B27 status and gender with sacroiliitis in patients with ankylosing spondylitis[J]. Pak J Med Sci,2014,30(1):22-27.
[18] YANG M,XU M,PAN X,et al. Epidemiological comparison of clinical manifestations according to HLA-B*27 carrier status of Chinese ankylosing spondylitis patients[J]. Tissue Antigens,2013,82(5):338-343.
[19] NEERINCKX B,KOLLNBERGER S,SHAW J,et al. No evidence for a direct role of HLA-B27 in pathological bone formation in axial SpA[J]. RMD Open,2017,3(1):e000451.
[20] DEUQUET J,LAUSCH E,SUPERTI-FURGA A,et al. The dark sides of capillary morphogenesis gene 2[J]. EMBO J,2012,31(1):3-13.
[21] XIA Y,CHEN K,ZHANG M H,et al. MicroRNA-124 involves in ankylosing spondylitis by targeting ANTXR2[J]. Modern Rheumatol,2015,25(5):784-789.
[22] MINAMIZAKI T,YOSHIKO Y,KOZAI K,et al. EP2 and EP4 receptors differentially mediate MAPK pathways underlying anabolic actions of prostaglandin E2 on bone formation in rat calvaria cell cultures[J]. Bone,2009,44(6):1177-1185.
[23] NAMIKAWA T,TERAI H,HOSHINO M,et al. Enhancing effects of a prostaglandin EP4 receptor agonist on recombinant human bone morphogenetic protein-2 mediated spine fusion in a rabbit model[J]. Spine,2007,32(21):2294-2299.
[24] WATANABE H,YAMADA Y. Chondrodysplasia of gene knockout mice for aggrecan and link protein[J]. Glycoconj J,2002,19(4-5):269-273.
[25] WATANABE H,YAMADA Y. Mice lacking link protein develop dwarfism and craniofacial abnormalities[J]. Nat Genet,1999,21(2):225-229.
[26] URANO T,NARUSAWA K,SHIRAKI M,et al. Single-nucleotide polymorphism in the hyaluronan and proteoglycan link protein 1(HAPLN1)gene is associated with spinal osteophyte formation and disc degeneration in Japanese women[J]. Eur Spine J,2011,20(4):572-577.
[27] ESKAN M A,JOTWANI R,ABE T,et al. The leukocyte integrin antagonist del-1 inhibits IL-17-mediated inflammatory bone loss[J]. Nat Immunol,2012,13(5):465-473.
[28] TAKAI A,INOMATA H,ARAKAWA A,et al. Anterior neural development requires del1,a matrix-associated protein that attenuates canonical Wnt signaling via the Ror2 pathway[J]. Development,2010,137(19):3293-3302.
[29] EHLEN H W,CHINENKOVA M,MOSER M,et al. Inactivation of anoctamin-6/Tmem16f,a regulator of phosphatidylserine scrambling in osteoblasts,leads to decreased mineral deposition in skeletal tissues[J]. J Bone Miner Res,2013,28(2):246-259.
[30] CORTES A,MAKSYMOWYCH W P,WORDSWORTH B P,et al. Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis[J]. Ann Rheum Dis,2015,74(7):1387-1393.
[31] MAKSYMOWYCH W P,ELEWAUT D,SCHETT G. Motion for debate:the development of ankylosis in ankylosing spondylitis is largely dependent on inflammation[J]. Arthritis Rheum,2012,64(6):1713-1719.
[32] LORIES R J,DOUGADOS M. Inflammation and ankylosis:still an enigmatic relationship in spondyloarthritis[J]. Ann Rheum Dis,2012,71(3):317-318.
[33] HAROON N,INMAN R D,LEARCH T J,et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis[J]. Arthritis Rheum,2013,65(10):2645-2654.
[34] RAMIRO S,VAN DER HEIJDE D,VAN TUBERGEN A,et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis:12-year longitudinal data from the OASIS cohort[J]. Ann Rheum Dis,2014,73(8):1455-1461.
[35] VAN DER HEIJDE D,MACHADO P,BRAUN J,et al. MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation:a multilevel analysis in patients with ankylosing spondylitis[J]. Ann Rheum Dis,2012,71(3):369-373.
[36] DIARRA D,STOLINA M,POLZER K,et al. Dickkopf-1 is a master regulator of joint remodeling[J]. Nat Med,2007,13(2):156-163.
[37] WANDERS A,VAN DER HEIJDE D,LANDEWE R,et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis:a randomized clinical trial[J]. Arthritis Rheum,2005,52(6):1756-1765.
[38] PODDUBNYY D,RUDWALEIT M,HAIBEL H,et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis:results from the German spondyloarthritis inception cohort[J]. Ann Rheum Dis,2012,71(10):1616-1622.
[39] VAN DER HEIJDE D,LANDEWE R,BARALIAKOS X,et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis[J]. Arthritis Rheum,2008,58(10):3063-3070.
[40] VAN DER HEIJDE D,LANDEWE R,EINSTEIN S,et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept[J]. Arthritis Rheum,2008,58(5):1324-1331.
[41] VAN DER HEIJDE D,SALONEN D,WEISSMAN B N,et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years[J]. Arthritis Res Ther,2009,11(4):R127.
[42] MOLNAR C,SCHERER A,BARALIAKOS X,et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity:results from the Swiss clinical quality management cohort[J]. Ann Rheum Dis,2018,77(1):63-69.
[43] MAAS F,SPOORENBERG A,BROUWER E,et al. Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-α blocking therapy:a prospective longitudinal observational cohort study[J]. PLoS One,2015,10(4):e0122693.
[44] BARALIAKOS X,HAIBEL H,LISTING J,et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis[J]. Ann Rheum Dis,2014,73(4):710-715.
[45] CHIOWCHANWISAWAKIT P,LAMBERT R G,CONNER-SPADY B,et al. Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis[J]. Arthritis Rheum,2011,63(8):2215-2225.
[46] BENJAMIN M,TOUMI H,SUZUKI D,et al. Evidence for a distinctive pattern of bone formation in enthesophytes[J]. Ann Rheum Dis,2009,68:1003-1010.
[47] MCINNES I,SCHETT G. Cytokines in the pathogenesis of rheumatoid arthritis[J]. Nat Immunol,2007,7(6):429-442.
[48] LORIES R J,DERESE I,LUYTEN F P. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis[J]. J Clin Invest,2005,115(6):1571-1579.
[49] CHEN D,XIE R,SHU B,et al. Wnt signaling in bone,kidney,intestine,and adipose tissue and interorgan interaction in aging[J]. Ann N Y Acad Sci,2019,1442(1):48-60.
[50] BáRDOS T,SZABó Z,CZIPRI M,et al. A longitudinal study on an autoimmune murine model of ankylosing spondylitis[J]. Ann Rheum Dis,2005,64(7):981-987.
[51] HAYNES K R,PETTIT A R,DUAN R,et al. Excessive bone formation in a mouse model of ankylosing spondylitis is associated with decreases in wnt pathway inhibitors[J]. Arthritis Res Ther,2012,14(6):R253.
[52] RUIZ-HEILAND G,HORN A,ZERR P,et al. Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis[J]. Ann Rheum Dis,2012,71(3):400-407.
[53] MAHMOUD A,FAYEZ D,GABAL M M,et al. Insight on bone morphogenetic protein 7 in ankylosing spondylitis and its association with disease activity and radiographic damage[J]. Electron Physician,2016,8(7):2670-2678.
[54] PARK M C,PARK Y B,LEE S K. Relationship of bone morphogenetic proteins to disease activity and radiographic damage in patients with ankylosing spondylitis[J]. Scand J Rheumatol,2008,37(3):200-204.
[55] KORKOSZ M,GASOWSKI J,LESZCZYNSKI P,et al. Effect of tumour necrosis factor-alpha inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity[J]. Scand J Rheumatol,2014,43(1):43-48.
[56] ZHANG L,OUYANG H,XIE Z,et al. Serum DKK-1 level in the development of ankylosing spondylitis and rheumatic arthritis:a meta-analysis[J]. Exp Mol Med,2016,48:e228.
[57] WU M,CHEN M,MA Y,et al. Dickkopf-1 in ankylosing spondylitis:Review and meta-analysis[J]. Clin Chim Acta,2018,481:177-183.
[58] DAOUSSIS D,LIOSSIS S N,SOLOMOU E E,et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis[J]. Arthritis Rheum,2010,62(1):150-158.
[59] MASI A T,NAIR K,ANDONIAN B J,et al. Integrative structural biomechanical concepts of ankylosing spondylitis[J]. Arthritis,2011,11:205904.
[60] MASI A T. Might axial myofascial properties and biomechanical mechanisms be relevant to ankylosing spondylitis and axial spondyloarthritis?[J]. Arthritis Res Ther,2014,16(2):107-112.
[61] JACQUES P,LAMBRECHT S,VERHEUGEN E,et al. Proof of concept:enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells[J]. Ann Rheum Dis,2014,73(2):437-445.